COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapiesANTI-CD20 요법으로 치료 중인 7명의 다발성 경화증 환자에서 COVID-19Case Reports Published on 2020-09-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] 바이오마커, 진단, [키워드] affected anti-CD20 antibody B cells CD20 Clinical course clinical picture Complication COVID-19 COVID-19 pandemic Diagnosis Evidence Humoral immunity Immunosuppressant immunosuppressants Immunosuppression Infection mAb mAbs material monoclonal antibodies monoclonal antibody Multiple multiple sclerosis Ocrelizumab pandemic Patient patients PCR presence of antibody protective role risk rituximab SARS-CoV-2 SARS-COV-2 infection sclerosis selective serology Seven severity Spread therapy treated Treatment Wuhan [DOI] 10.1016/j.msard.2020.102306 PMC 바로가기 [Article Type] Case Reports
Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S 1Short Paper Published on 2020-08-262022-11-01 Journal: Epidemiology and Infection [Category] COVID-19, MERS, [키워드] 95% CI 95% confidence interval Analysing clinical picture COVID COVID patient COVID-19 FIVE Frequency Guillain–Barrè syndrome Guillain–Barré syndrome hospitalisation Infection less manifestation meningoencephalitis Myopericarditis Odds ratio outbreak Pancreatitis Patient reported SARS-CoV-2 Spanish Spontaneous pneumothorax triggered viral infections [DOI] 10.1017/S0950268820001910 PMC 바로가기 [Article Type] Short Paper
Diabetic Ketoacidosis Precipitated by COVID-19 in Patients Without Respiratory Symptoms: Case ReportsEmergency Medicine Published on 2020-08-252022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Bacterial clinical outcomes clinical picture Coinfection Comorbidities coronavirus disease COVID-19 diabetes Diabetes Mellitus Diabetic diagnostic test ketoacidosis Mortality older patient outcome Patient report respiratory respiratory symptoms risk factor SARS-CoV-2 severe COVID-19 patient Treatment [DOI] 10.7759/cureus.10031 PMC 바로가기 [Article Type] Emergency Medicine
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case reportCase Report Published on 2020-08-242022-10-28 Journal: BMC Pregnancy and Childbirth [Category] COVID-19, MERS, [키워드] association Asymptomatic asymptomatic patient bleeding Case report Cesarean section clinical picture Coagulopathy concerning contribute COVID COVID-19 D-dimer disease Effect Elevation Evidence expected fibrinogen help higher risk identify infected with SARS-CoV-2 initial International intraoperative Laboratory Laboratory tests normalized Patient Platelets Pregnancy pregnant pregnant population Prothrombin time SARS-CoV-2 SARS-COV-2 infection Scientific community significantly more the patient unique [DOI] 10.1186/s12884-020-03140-2 PMC 바로가기 [Article Type] Case Report
Case Report: A COVID-19 Patient Presenting with Mild RhabdomyolysisArticles Published on 2020-08-192022-10-28 Journal: The American Journal of Tropical Medicine and Hygi [Category] COVID-19, MERS, SARS, [키워드] Admission China clinical picture Complication cough COVID-19 diagnosed Diagnosis diagnosis of COVID-19 Dyspnea Enzymes Evidence explain fatigue Fever had no initiated lack Mild myalgia novel corona virus Pain pandemic Patient patient with COVID-19 Pneumonia reported rhabdomyolysis SARS-CoV-2 Symptom the disease the WHO Treatment typical symptom viral infection Wuhan [DOI] 10.4269/ajtmh.20-0583 PMC 바로가기 [Article Type] Articles
Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary HypertensionReview Published on 2020-07-312022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] affecting angiotensin-converting enzyme 2 Anticoagulant benefit cardiovascular disease Characteristics clinical entities clinical picture Comorbidities condition COVID-19 COVID-19 case described dysfunction Effect Endothelial dysfunction Endothelium explain feature health emergency high mortality rate incidence Inflammation International involved management mechanism PAH Particular pathophysiological pathophysiology Patient Precapillary protective effect pulmonary pulmonary arterial hypertension pulmonary circulation pulmonary hypertension reported respiratory infections scenario severity severity of COVID-19 similarity specific treatment thromboembolic thrombosis vasoconstriction ventilation/perfusion [DOI] 10.3390/diagnostics10080548 PMC 바로가기 [Article Type] Review
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial코비드-19-실험 약물 및 기전(TACTIC-E)으로 입원한 ICu 전 환자에 대한 다중 암 치료 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] able to swallow adaptive Adaptive trial added Admission age Ambrisentan Analysis approved Arm ARMS balloon pump balloon pump) baseline benefit Biomarker blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not cardiac cardiovascular complications cells clearance clinical endpoint Clinical endpoints clinical picture clinically Combination comparator comparison Complete Composite Course COVID-19 COVID-19 infection creatinine creatinine clearance CRP Dapagliflozin Data analysis Day death defined demonstrated determine diabetes Diagnosis discretion disease dissemination drug drugs ECMO EDP1815 Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT Evidence evidence of exclusion criteria Experimental drugs failure feature fixed foundation Gault Gender group hypertension immunomodulation immunomodulatory incidence include Inclusion independent independent data monitoring committee Inotropes Intervention Invasive mechanical ventilation investigator Laboratory late stage male mechanism membrane neutrophil Neutrophils NHS number objective Occurrence on admission once daily Open-label open-label trial opinion option Organ failure organ support Other outcome Oxygenation pandemic Parallel Arm participant Patient patients with COVID-19 performed phase platform Platform trial positive positive COVID-19 predicted Primary outcome principal investigator progression protocol Radiographic radiological randomisation randomised Randomized controlled trial recruited reduce Registered related disease renal renal failure risk Sample size severity Standard of care status stratified Study protocol subject Support tablets the patient therapy Treatment treatment arm Trial Trial registration triggered Trust university website [DOI] 10.1186/s13063-020-04618-2 PMC 바로가기 [Article Type] Letter
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapyInterpretive Synthesis Review Article Published on 2020-07-172022-10-30 Journal: Immunologic research [Category] COVID-19, MERS, [키워드] addition Adult-onset Still’s disease Anti-viral association asymptomatic patient catastrophic Catastrophic antiphospholipid syndrome characterized clinical picture conditions COVID-19 COVID-19 pandemic COVID-19 patient cytokine release Deferoxamine demonstrated develop disease elevated ferritin fibrosis hemophagocytic lymphohistiocytosis Hyperferritinemia Hyperferritinemic IL-6 immunomodulatory effect inflammatory process iron iron chelation Iron depletion therapy life-threatening lymphopenia macrophage activation syndrome Mortality Numerous occur other disease pathogenic SARS-CoV-2 SARS-COV-2 infection Septic shock severe pulmonary involvement sustained syndrome Therapeutic approach therapy tissues Treatment [DOI] 10.1007/s12026-020-09145-5 PMC 바로가기 [Article Type] Interpretive Synthesis Review Article
Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 TreatmentReview Article Published on 2020-07-162022-10-31 Journal: Mediators of Inflammation [Category] COVID-19, MERS, SARS, [키워드] Activation Affect autophagy build caused clinical picture COVID-19 damage-associated molecular pattern damaged DAMPs excessive inflammatory response HMGB1 immune response increase in induce Inflammation Innate immunity lung cell NETosis NETs neutrophil Neutrophil extracellular trap new coronavirus SARS-CoV-2 pandemic disease pattern Potential released Respiratory system robust SARS-COV-2 infection sustained target targeted therapy the disease Treatment viruses [DOI] 10.1155/2020/7527953 PMC 바로가기 [Article Type] Review Article
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients – mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trialICu 전 환자의 Covid-19에 대한 용도 변경 면역조절 약물 - Covid-19로 입원한 ICu 전 환자에 대한 다중 암 치료 연구 – 용도 변경 약물(TACTIC-R): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-082022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] Administered Admission age Analysis Arm ARMS balloon pump balloon pump) Baricitinib baseline blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not candidate cardiac clearance clinical picture college comparator comparison Complete COVID-19 infection creatinine creatinine clearance CRP Data analysis Data monitoring committee Day death defined determine diabetes Diagnosis discharge disease dissemination dose drug Drug evaluation Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT event exclusion criteria feature fixed foundation Gault Gender hypertension IDMC immunomodulatory immunomodulatory drug immunomodulatory drugs Immunomodulatory therapies immunomodulatory therapy incidence include Inclusion independent data monitoring committee initial Inotropes interim analysis Intervention intravenously Invasive mechanical ventilation investigator ISRCTN late stage Local male membrane neutrophil Neutrophils NHS number objective on admission once daily Open-label open-label trial opinion Organ failure organ support outcome Oxygenation participant Patient phase Platform trial positive positive COVID-19 predicted Primary outcome progression Prophylaxis protocol Radiographic radiological randomisation randomised randomised controlled trial Ravulizumab recruited recruitment reduce reduced regimen Registered related disease renal renal failure Repurposed drugs risk Sample size scalability selected severity SOC stage 2 Standard of care status stratified Study protocol subject Support Toxicity treatment arm Trial Trial registration triggered Trust university university hospital Venous Thromboembolism website [DOI] 10.1186/s13063-020-04535-4 PMC 바로가기 [Article Type] Letter